RHEUMATOID ARTHRITIS - ADALIMUMAB, ETANERCEPT AND INFLIXIMAB (SEQUENTIAL USE)
NICE Appraisal
Rheumatoid arthritis - adalimumab, etanercept and infliximab (sequential use) (suspended)
DSU Reports
Sequential TNF-a inhibitors and non biologic DMARDs - analysis of the national databank for rheumatic diseases (March 2008)
The sequential use of TNF-a inhibitors - update to a report by the decision support unit (January 2008)
The effectiveness of non biologic DMARDs after anti TNF-a inhibitor failure (January 2008)
Related publication
S Lloyd, S Bujkiewicz, A Wailoo, A Sutton, D Scott. The effectiveness of anti-TNF-a therapies when used sequentially in rheumatoid arthritis patients: a systematic review and meta-analysis. Rheumatology 2010; Vol 49 (12): 2313-2321.
RHEUMATOID ARTHRITIS - ADALIMUMAB, ETANERCEPT AND INFLIXIMAB
NICE Appraisal
TA130 Adalimumab, etanercept and infliximab for the treatment of rheumatoid arthritis (October 2007)
DSU Report